S
Sean K. Kelley
Researcher at Genentech
Publications - 14
Citations - 2393
Sean K. Kelley is an academic researcher from Genentech. The author has contributed to research in topics: Pharmacodynamics & Apoptosis. The author has an hindex of 11, co-authored 14 publications receiving 2333 citations. Previous affiliations of Sean K. Kelley include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
David A. Lawrence,Zahra Shahrokh,Scot A. Marsters,Kirsten Achilles,Danny Shih,Barbara Mounho,Kenneth J. Hillan,Klara Totpal,Laura DeForge,Peter Schow,Jeffrey Hooley,Steve Sherwood,Roger Pai,Susan Leung,Lolo Khan,Brian Gliniak,Jeanine L. Bussiere,Craig A. Smith,Stephen S. Strom,Sean K. Kelley,Judith A. Fox,Deborah Thomas,Avi Ashkenazi +22 more
TL;DR: These findings not only provide a novel insight into the pathogenesis of the transplant-related atherosclerosis, but also point to a new therapeutic strategy that involves targeting of homing, differentiation and proliferation of putative smooth-muscle progenitor cells derived from the recipient.
Journal ArticleDOI
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
Roy S. Herbst,David H. Johnson,Eric Mininberg,David P. Carbone,Ted Henderson,Edward S. Kim,George R. Blumenschein,Jack Lee,Diane D. Liu,Mylene T. Truong,Waun Ki Hong,Hai T. Tran,Anne Tsao,Dong Xie,D. Ramies,Robert Mass,Somasekar Seshagiri,David A. Eberhard,Sean K. Kelley,Alan B. Sandler +19 more
TL;DR: Encouraging antitumor activity and safety of A + T support further development of this combination for patients with advanced NSCLC and other solid tumors.
Journal Article
Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety
Sean K. Kelley,Louise A. Harris,David Xie,Laura DeForge,Klara Totpal,Jeanine L. Bussiere,Judith A. Fox +6 more
TL;DR: Estimates of Apo2L/TRAIL kinetics in humans were provided, suggesting that on a milligram per kilogram basis, doses significantly lower than those used in xenograft studies could be effective in humans.
Journal ArticleDOI
Targeting death receptors in cancer with Apo2L/TRAIL.
Sean K. Kelley,Avi Ashkenazi +1 more
TL;DR: Apo2L/TRAIL might be effective against tumors that have acquired resistance to conventional therapy, and could augment the efficacy of current treatment in a wide spectrum of cancers.
Journal ArticleDOI
Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) Early Termination Due To Increased Toxicities
Wells A. Messersmith,Daniel A. Laheru,N. Senzer,Ross C. Donehower,Paula Grouleff,Theresa Rogers,Sean K. Kelley,David Ramies,Bert L. Lum,Manuel Hidalgo +9 more
TL;DR: FOLFIRI combined with erlotinib causes excessive toxicity at reduced doses, contrast with available data regarding the optimal safety profile of trials combining small molecule epidermal growth factor receptor inhibitors with other conventional chemotherapy and highlight the need to perform safety-oriented studies of such combinations.